Company signals · Biotech & Pharma
Novartis AG
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: The wider read — a Talent Market Index of 104.6 (Hot), down 1.9 month-on-month — shows Americas signal flow rising (+2.1pts).
Novartis AG: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies.
Signals at Novartis AG
MitchelLake in this thematic
More signals across Biotech & Pharma
Leadership Change · Americas
Flagship Pioneering →Flagship Pioneering, a scientific innovation engine, appointed two Executive Partners: Fidah Alsagoff (Head of Global Initiatives) and Maggie Sahlman (Head of Fundraising and Investor Relations).
Ma Activity · Americas
Bristol Myers Squibb →Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal
Capital Raising · Americas
Ratio Therapeutics →Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Leadership Change · Americas
Teva Pharmaceuticals →Teva Pharmaceuticals CEO Richard Francis discusses Q2 earnings, drug pipeline, and the company's direct listing on NYSE. Signals leadership visibility and capital market transition.
Product Launch · Americas
Amgen →Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.
Ma Activity · Americas
Biogen →Biogen is relying on drugs acquired through the Apellis deal to offset weak sales of Leqembi (Alzheimer's drug), indicating strategic dependence on M&A to bolster pipeline performance.
Intelligence powered by Autonodal ↗